Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.58 |
| ▸ | CTSK | P43235 | 15/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21663693 | 0.89 | CTSS (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL15083610 | 0.89 | CTSS (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL21689270 | 0.89 | CTSS (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL16289538 | 0.89 | CTSS (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL15083497 | 0.87 | CTSS (0.57) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL16289144 | 0.87 | CTSS (0.57) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL14803767 | 0.86 | PPARG (0.53) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL20045974 | 0.86 | PPARG (0.53) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL17910300 | 0.86 | PPARG (0.55) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL17910302 | 0.86 | PPARG (0.55) | CTSSCTSKCTSBCTSLPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CTSS 273/4885CTSK 188/4885CTSB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.